
Ozisiran Delivers Sustained Viral and Antigen Suppression in Chronic Hepatitis D – Preliminary Interim Phase 2a Results
Preliminary results from the ongoing Phase 2a study evaluating ozisiran (RBD1016) in patients with chronic hepatitis D (HDV) [NCT06649266] were






















































